Last edition
News about Global Pharma
InnoCare Secures China's NMPA Approval for Minjuvi Combo in Treating Relapsed DLBCL
InnoCare Pharma has received China National Medical Products Administration (NMPA) approval for Minjuvi (tafasitamab) plus lenalidomide to treat adult patients with relapsed or refractory DLBCL in China who are ineligible for stem cell transplant.
Global Pharma | 23/05/2025 | By Manvi
NextCell and Fujifilm Irvine Scientific Enter Strategic Pact
The collaboration between NextCell Pharma and Fujifilm Irvine Scientific Inc. will bring together their core expertise in mesenchymal stromal cells (MSCs) and raw materials for the life science sector.
Global Pharma | 23/05/2025 | By Manvi
Venus Remedies Secures Ukrainian GNP Renewal for Baddi Facility
Venus Remedies aims to strengthen its global pharmaceutical presence after the renewal of GMP certification from Ukraine's State Service on Medicines and Drugs Control (SMDC) for its Unit-II manufacturing facility located in Baddi, Himachal Pradesh.
Global Pharma | 23/05/2025 | By Manvi
Malaysian Government Extends Insulin Supply Contract with Biocon Biologics
The Malaysian Health Ministry has extended the contract with Biocon Biologics to continue insulin supply under the partnership with Duopharma and Biocon Sdn. Bhd.
Global Pharma | 23/05/2025 | By Manvi
Bayer Gets Regulatory Approval of Aflibercept 8 MG in China
China gives approval to Bayer over the Application for Regulatory Approval of Aflibercept 8 MG used for the treatment of neovascular (wet) age-related macular degeneration (nAMD).
Global Pharma | 23/05/2025 | By Manvi
Ecolab Life Sciences Opens New Bioprocessing Applications Laboratory in US
Ecolab’s new bioprocessing applications laboratory in the US will support biopharma and CDMOs with bioprocessing applications and purification development.
Global Pharma | 23/05/2025 | By Manvi
Celltrion's YUFLYMA Secures FDA Interchangeability Designation
Celltrion has announced that the FDA has granted expanded interchangeable designation to YUFLYMA (adalimumab-aaty), now covering prefilled syringe (40mg) and autoinjectors (40mg and 80mg) presentations, making it fully interchangeable with Humira.
Global Pharma | 23/05/2025 | By Manvi
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
Pfizer and Chinese biopharmaceutical company 3SBio have entered into a licensing agreement valued at approximately USD 6 billion for the development, manufacturing, and commercialisation of SSGJ-707, a drug candidate targeting various cancers.
Global Pharma | 22/05/2025 | By Manvi
Eli Lilly’s Kisunla (donanemab) has received marketing authorisation from Australia’s Therapeutic Goods Administration (TGA), becoming the country’s first approved amyloid-targeting treatment for early Alzheimer’s disease.
Global Pharma | 22/05/2025 | By Manvi
Tampa General Elevates Heart Care with AI-Powered 512-Slice CT Scanners from GE Healthcare
The advanced scanners leverage artificial intelligence (AI) and machine learning technologies to deliver faster, clearer and more precise scans, refining diagnoses and treatments of cardiovascular diseases.
Global Pharma | 22/05/2025 | By Manvi
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy